human dhodh

DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor. The IC50 values of PfDHODH and HsDHODH are 4 μM and 0.18 μM, respectively. DHODH-IN-4 has antimalarial activity.

hDHODH-IN-4 (DHODH-IN-5) is a potent inhibitor of human dihydrogen dehydrogenase (DHODH). For human recombinant DHODH, its pIC50 is 7.8. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8.

hDHODH-IN-7 (DHODH-IN-9) is a nitrogen-containing analog and is a human dihydrorotatory dehydrogenase inhibitor. hDHODH-IN-7 and pMIC50 of 7.4 have antiviral effects.

Olorofim(F-901318)is a novel selective antifungal compound targeting pyrimidine biosynthesis in mycobacteria, with inhibitory effect on Aspergillus fumigatus DHODH (IC50: 44 nM), but little inhibitory effect on human DHODH (>100 uM).Olorofim has good efficacy against a variety of pathogenic filamentous and dimorphic fungi, such as Penicillium spp, P. dermatitidis spp and Fusarium spp.

DHODH-IN-17 is a human DHODH inhibitor with an IC50 of 0.40 μM. DHODH-IN-17 is a 2- anilino nicotinic acid that can be used in the study of acute myeloid leukemia (AML).

BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of myeloid malignancies.BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity.

Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity, showing potential as a first-in-class candidate in AML [Acute Myeloid Leukemia].

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

BRD7539B is a Dihydroorotate dehydrogenase (DHODH) inhibitor . RD7539 shows to target PfDHODH (IC50 = 0.033 μM) selectively over human (Hs) DHODH (IC50 > 50 μM).

DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

DHODH-IN-18 is a human DHODH inhibitor with an IC50 value of 0.2 nM.

Dhodh-in-20 (Compound 133) is a potent inhibitor of DHODH. Among them, DHODH is an iron-containing flavin-dependent enzyme that is present in the inner membrane of human mitochondria. DHODH-IN-20 showed an inhibitory effect on tumor growth. DHODH-IN-20 has the potential to be used in the study of acute myeloid leukemia.

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].

DHODH-IN-24 (compound 16) serves as a powerful inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 91 nM [1].

DHODH-IN-25 (Compound 25) serves as an orally active inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting a potent IC50 of 5.4 nM against human DHODH. It is applicable in research related to acute myeloid leukemia (AML) [1].

PfDHODH-IN-2 is a dihydrothiophenone derivative, is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH, IC50 : 1.11 μM) inhibitor . It is used an antimalarial agent and can be used for the research of malaria

(E/Z)-Ginkgolic Acid C17:2 (Ginkgolic Acid C17:2) is a natural product extracted from Ginkgo biloba that targets human dihydroorotate dehydrogenase (DHODH).